Filing Flows › West Pharmaceutical Services (WST) › Guidance & outlook

West Pharmaceutical Services (WST) guidance and outlook

West Pharmaceutical Services (WST) raised some and lowered other parts of its guidance on Oct 29, 2026: Revenue $3.4B for FY2026; EPS $9.38–$9.48 for FY2026; Revenue +6.6% for FY2026; Capital expenditures $215M–$220M for FY2026.

Guidance and outlook

Met or beat 5 of 5 guided periods. Grey: the last range guided before the figures came out; dot: the reported figure.

Met or beat 3 of 3 guided periods. Grey: the last range guided before the figures came out; dot: the reported figure.

Latest guidance

Metric	Period	Range	Change
Revenue	FY2026	$3.4B	raised
EPS	FY2026	$9.38–$9.48	raised
Revenue	FY2026	+19.7%	new
Revenue	FY2026	+6.6%	lowered
Revenue	FY2026	+11.3% to +11.6%	raised
Capital expenditures	FY2026	$215M–$220M	lowered
EPS	FY2026	$7.29	reaffirmed
EPS	FY2026	+28.7% to +30%	raised

From the earnings release filed Oct 29, 2026 (8-K on EDGAR).

West Pharmaceutical Services' latest quarter

West Pharmaceutical Services, Q3 2026: revenue $874M (+9% year over year), operating margin 30.6%, net earnings $214M, operating cash flow $190M. The chart follows the revenue to costs, profit and cash.

Questions

Did West Pharmaceutical Services raise or lower its guidance?

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.